News
PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases
PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease and other neurodegenerative diseases, today announces a new epigenetics collaboration with Sheffield Hallam University. This partnership will focus on ‘gene-based environmental biomarkers,’ known as epigenetic markers, for calculating risk scores for Alzheimer’s disease. Together with ALZmetrixTM, PharmaKure’s blood-based biomarker, this will increase the […]